The authors discuss how more efforts need to ensure the methods used to measure the “value” of new therapies include factors that reflect patient heterogeneity.
Amy Miller, PhD
Advertisement
Articles by Amy Miller, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
3
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
4
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
5